- Jin Soo LEE, M.D., Ph.D.
- Faculty Appointment:
- Emeritus Professor, National Cancer Center Graduate School of Cancer Science and Policy
Adjunct Professor, University of Texas M.D. Anderson Cancer Center; Department of Thoracic/Head and Neck
- Area of Expertise
- Thoracic/Head and Neck Medical Oncology
- Previous Appointment(s) Held
- 4th and 5th President, National Cancer Center
Former(1st)President, National Cancer Center Graduate School of Cancer Science and Policy
Director, Research Institute, National Cancer Center
Director, National Cancer Center Hospital
Professor of Medicine, University of Texas M. D. Anderson Cancer Center; Department of Thoracic/Head and Neck Medical Oncology
- Educational Background
- 1970 Seoul National University; Seoul, Korea; Premedical Degree
1974 Seoul National University; College of Medicine; Seoul, Korea; M.D.
1976 Seoul National University; School of Public Health; Seoul, Korea; M.P.H.
2007 Seoul National University; School of Public Health; Seoul, Korea; Ph.D.
- Research Interests
- Dr. Lee, Jin Soo, President of National Cancer Center Korea and Adjunct Professor of the MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, Houston, Texas, earned his MD from Seoul National University, Korea, and completed residency training in Internal Medicine in Chicago, Illinois and medical oncology fellowship at MD Anderson Cancer Center, Houston, Texas.
His current research interests include cancer susceptibility and epidemiology, biomarkers, and druggable targets, treatment of lung cancer with novel targeted agents and combined treatment modalities.
- International Collaboration
- Congress President, Local Organizing Committee, 12th World Conference on Lung Cancer, Seoul
Board of Directors, International Association for the Study of Lung Cancer(IASLC)
Member, American Society of Clinical Oncology(ASCO)
Member, American Association for Cancer Research(AACR)
Member, American College of Physicians.
- Selected List
- Yi Long Wu, Lee JS, Sumitra Thongprasert, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double blind trial. Lancet Oncology.2013 Jul;14(8):684-5
Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Research and Treatment. 2013 Mar;45(1):15-21
HanJY, ParkKC, KimSW, LeeDH, KimHY, KimHT, AhnMJ, Yun T, AhnJS, SuhCW, Lee J, YoonSJ, HanJH, LeeJW, JoSJ, Lee JS. First-SIGNAL: fist-line single agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Journal of Clinical Oncology. 2012;30(10);1122-1128.
Yoon KA, Lee YJ, Han JY, Kim HT, Yun T, Lee GK, Kim HY, Lee JS. Circulating cell free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.Clincial Cancer Research.2011;17(16);5179~5187
Han JY, Yoon KA, Park JH, Lee YJ, Lee GK, Han JH, Yoon SJ, Yun T, Kim HT, Lee JS. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.Cancer. 2011;117(14);3201~3208
Han JY,LimKY, YuSY, YunT, KimHT, Lee JS. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer. 2011;117(10);2178~2185
HanJY, LimKY, YuSY, YunT, KimHT, Lee JS. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.Cancer.2011;117(10);2178~2185
HanJY, LeeSH, YooNJ, LeeSH, MoonYJ, Yun T, KimHT, Lee JS. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.Clinical Cancer Research.2011;17(6);1553~1560
YoonKA, ParkJH, HanJY, ParkSH, LeeGK, HanJY, ZoJI, KimJS, Lee, Atsushi Takahashi, Michiaki Kubo, Yusuke Nakamura, Lee JS. A Genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population.Human Molecular Genetics.2010;19(24);4948~4954.
Daiki Miki, Michiaki Kubo, Atsushi Takahashi, Kyong Ah Yoon, Jeong Seon KIM, Geon Kook LEE, Jae Ill Zo, Lee JS, et al.Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.Nature Genetics.2010;42;893~896
Tony S.K. Mok, Yi-Long Wu, Chong-Jen Yu, Caicun Zhou, Yuh-Min Chen, Li Zhang, Jorge Ignacio,Meilin Liao, VichienSrimuninnimit, Michael J. Boyer, Marina Chua-Tan, ViroteSriuranpong, Aru W. Sudoyo, Kate Jin, Michael Johnston, Winsome Chui, Lee JS. Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2009;27(30):5080~5087.
Giorgio V.Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, RaghunadharaoDigumarti, Mauro Zukin, Lee JS, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2008. 26:3543~3551
Yoon KA, Park SH, Hwangbo B, Shin HD, Cheong HS, Shin HR, Lee JS. Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer. Carcinogenesis.2007;28(9);1971-1977
HanJY, LimHS, Shin ES, YooYK, Park YH, Lee JE, Jang IJ , Lee DH, Lee JS. Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non-Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin. Journal of Clinical Oncology. 2006;24;2237-2244.
KA Yoon, B Hwangbo, IJ Kim, SH Park, HS Kim, HJ Kee, JE Lee, YK Jang, JG Park, Lee JS. Novel Polymorphisms in the SUV39H2 Histone Methyltransferase and the Risk of Lung Cancer. Carcinogenesis.2006;27(11);2217-2222
Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS. Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smkers.Clinicial Cancer Research. 2005;11(8):3032-3037
Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H. Radiosensitivity enhancement by combined treatment of celecoxib and Gefitinib on human lung cancer cells. Clinicial Cancer Research.2006 ;15;12(16):4989-99.
Han JY, Lee DH, Kim HY, Kim EA, Lee JJ, Ju SY, Shin EH, Lee JS. A phase II study of weekly irinotecan and capecitabine in patients with previously treated Non-Small Cell Lung Cancer.Clinicial Cancer Research. 2003;9:5909-14